Have you be en wondering why North Americans are some of the least healthy people on the planet? As much as I’d like to blame the medical industry, I think much of it is our own fault. I just found out that we are eating 95,000 metric tons of MSG (monosodium glutamate)! Haven't we got the message? We've known for 30 years that there's a problem with this stuff. It's what's known as an exitotoxin. It excites our nervous system too much. Now I know you think that you don't eat MSG because you either don't eat at Chinese restaurants or you make sure to always ask if your favorite Chinese restaurant uses MSG. Well it's the American food industry that using the 95,000 tons of this toxin--not the Chinese restaurants! Look at your food labels and see if you see Glutamic Acid or Hydrolyzed Protein--that's MSG. Even if you don't see it, it may still be there because companies don't have to show all the ingredients. There's evidence connecting MSG to fibromyalgia, diabetes, Alzheimer's and many other diseases that have been increasing lately. Don't expect the FDA to protect you from a chemical that is selling as well as MSG. The MSG industry will make sure that it stays on the store shelves and in your favorite American restaurants. Here's a video by Dr. Vincent Bellonzi about the problems that MSG creates in the body. Folks, please avoid MSG. Eat natural foods, not processed.
Research
Here's just a few studies about the effects of MSG to give you an idea; there's plenty more where these came from:
- RELIEF OF FIBROMYALGIA SYMPTOMS FOLLOWING DISCONTINUATION OF DIETARY EXCITOTOXINS, JD Smith, CM Terpening, SO Schmidt, and JG Gums. The Annals of Pharmacotherapy: Vol. 35, No. 6, pp. 702-706. DOI 10.1345/aph.10254. CONCLUSIONS: The elimination of MSG and other excitotoxins from the diets of patients with fibromyalgia offers a benign treatment option that has the potential for dramatic results in a subset of patients
- THE ROLE OF GLUTAMATE IN CHRONIC INFLAMMATORY PAIN AND PAINFUL PERIPHERAL NEUROPATHIES, Gary J. Bennett, Ph.D., Allegheny University of the Health Sciences
- MANIPULATING GLUTAMATERGIC NEUROTRANSMISSION FOR THERAPEUTIC GAIN: THE EXAMPLE OF BRAIN ISCHEMIA, Dennis W. Choi, M.D., Ph.D., Washington University School of Medicine
- GLUTAMATERGIC MECHANISMS IN THE CAUSE AND TREATMENT OF PARKINSON'S DISEASE, J. Timothy Greenamyre, M.D., Ph.D., Emory University
- ROLE OF GLUTAMATE RECEPTOR MATURATION IN PERINATAL BRAIN INJURY, Frances E. Jensen, M.D., Children's Hospital (Boston) and Harvard Medical School
- EFFECT OF GLUTAMATE BLOCKERS ON HUMAN PAIN, Mitchell B. Max, M.D., National Institute of Dental Research, National Institutes of Health
- GLUTAMATE RECEPTOR PLASTICITY IN THE HIPPOCAMPUS: IMPLICATIONS FOR AGING, John H. Morrison, Ph.D., Fishberg Research Center for Neurobiology, Mount Sinai School of Medicine
- GLUTAMATE NEUROTRANSMISSION IN EPILEPSY: NEW TREATMENT STRATEGIES, Michael A. Rogawski, M.D., Ph.D., National Institute of Neurological Disorders and Stroke, National Institutes of Health
- SCHIZOPHRENIA: A GLUTAMATERGIC PERSPECTIVE, Stephen R. Zukin, M.D., National Institute on Drug Abuse, National Institutes of Health
